OSE Immunotherapeutics Reports Promising Phase 2 Trial Outcomes for Lusvertikimab in Ulcerative Colitis Treatment.

IASO Biotechnology announced that the FDA has approved its application for a new drug, Equecabtagene Autoleucel (Eque-cel), a fully human anti-BCMA CAR T cell therapy.

Enterprise Therapeutics has today revealed that the first participant with cystic fibrosis has been administered a dose in its Phase 2a study of ETD001.

Merck Reveals Preliminary Findings from Phase 2b/3 Study of Clesrovimab (MK-1654), an Experimental Monoclonal Antibody for RSV Prevention in Infants.

FDA Greenlights Samsung Bioepis' EPYSQLI® (eculizumab-aagh) as a Biosimilar to Soliris (eculizumab).

Zymeworks Receives FDA Approval for ZW191 Investigational New Drug Application, a Cutting-Edge Folate Receptor-⍺ Targeted Topoisomerase I Inhibitor Antibody-Drug Conjugate.

STADA and Alvotech introduce Uzpruvo, the initial ustekinumab biosimilar approved against Stelara, in Europe.

Gan & Lee Pharmaceuticals' GZR18 injection, a bi-weekly GLP-1 receptor agonist, showed a 17.29% weight reduction after 30 weeks in a Phase IIb study.

Nuvalent reported the launch of HEROEX-1, its Phase 1a/1b clinical study testing the new HER2-selective inhibitor NVL-330.

Johnson & Johnson is requesting U.S. FDA approval for SPRAVATO® (esketamine) as the sole treatment for adults with treatment-resistant depression.

This study assessed the safety, tolerability, and pharmacokinetics of their leading lipidated IL-22 candidate, CK-0045.

The European Medicines Agency has approved Bristol Myers Squibb's application to use Opdivo (nivolumab) and Yervoy (ipilimumab) as initial treatments.